The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies
Abstract Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment op...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | ImmunoMedicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/imed.1039 |
| _version_ | 1797853369375653888 |
|---|---|
| author | Elaine Tan Su Yin Yong Xian Hu He Huang |
| author_facet | Elaine Tan Su Yin Yong Xian Hu He Huang |
| author_sort | Elaine Tan Su Yin |
| collection | DOAJ |
| description | Abstract Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment option for relapsed or refractory non‐Hodgkin lymphoma (NHL). CD20 CAR T‐cell infusion has achieved remarkable clinical outcomes in patients with B‐cell malignancies. This review will cover the current situations, advantages, limitations, prospects, and application of CD20 CAR T‐cell therapy. |
| first_indexed | 2024-04-09T19:48:30Z |
| format | Article |
| id | doaj.art-32939fc747924d238e8275448fc36a1f |
| institution | Directory Open Access Journal |
| issn | 2510-5345 |
| language | English |
| last_indexed | 2024-04-09T19:48:30Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ImmunoMedicine |
| spelling | doaj.art-32939fc747924d238e8275448fc36a1f2023-04-03T10:35:21ZengWileyImmunoMedicine2510-53452022-06-0121n/an/a10.1002/imed.1039The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignanciesElaine Tan Su Yin0Yong Xian Hu1He Huang2Bone Marrow Transplantation Center The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou ChinaBone Marrow Transplantation Center The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou ChinaBone Marrow Transplantation Center The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou ChinaAbstract Chimeric antigen receptors (CAR) T‐cell therapy is one of the most effective treatments in curing hematologic malignancies. Besides the four CD19 CAR T‐cells therapy recently approved by the US Food and Drug Administration (FDA), CD20 CAR T‐cell therapy is now another effective treatment option for relapsed or refractory non‐Hodgkin lymphoma (NHL). CD20 CAR T‐cell infusion has achieved remarkable clinical outcomes in patients with B‐cell malignancies. This review will cover the current situations, advantages, limitations, prospects, and application of CD20 CAR T‐cell therapy.https://doi.org/10.1002/imed.1039CD20chimeric antigen receptor (CAR) T‐cellsimmunotherapynon‐Hodgkin lymphoma (NHL) |
| spellingShingle | Elaine Tan Su Yin Yong Xian Hu He Huang The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies ImmunoMedicine CD20 chimeric antigen receptor (CAR) T‐cells immunotherapy non‐Hodgkin lymphoma (NHL) |
| title | The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies |
| title_full | The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies |
| title_fullStr | The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies |
| title_full_unstemmed | The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies |
| title_short | The breakthrough and the future: CD20 chimeric antigen receptor T‐cell therapy for hematologic malignancies |
| title_sort | breakthrough and the future cd20 chimeric antigen receptor t cell therapy for hematologic malignancies |
| topic | CD20 chimeric antigen receptor (CAR) T‐cells immunotherapy non‐Hodgkin lymphoma (NHL) |
| url | https://doi.org/10.1002/imed.1039 |
| work_keys_str_mv | AT elainetansuyin thebreakthroughandthefuturecd20chimericantigenreceptortcelltherapyforhematologicmalignancies AT yongxianhu thebreakthroughandthefuturecd20chimericantigenreceptortcelltherapyforhematologicmalignancies AT hehuang thebreakthroughandthefuturecd20chimericantigenreceptortcelltherapyforhematologicmalignancies AT elainetansuyin breakthroughandthefuturecd20chimericantigenreceptortcelltherapyforhematologicmalignancies AT yongxianhu breakthroughandthefuturecd20chimericantigenreceptortcelltherapyforhematologicmalignancies AT hehuang breakthroughandthefuturecd20chimericantigenreceptortcelltherapyforhematologicmalignancies |